Skip to search formSkip to main contentSkip to account menu

AS703569

Known as: Aurora Kinase Inhibitor AS703569 
National Institutes of Health

Related topics

Related topics

2 relations
Aurora kinase inhibitor R763

Broader (1)

MSC1992371A

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Abstract 2754: Phase I and pharmacokinetic (PK) study of two regimens combining the aurora kinase inhibitor AS703569 and gemcitabine in patients with advanced solid tumors
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Background: AS703569 is an orally available, ATP… 
2010
2010
Abstract 4433: A Phase I study of two dosing regimens of oral AS703569, an inhibitor of aurora kinase and other kinases, in patients with hematologic malignancies
Background: AS703569 is a novel, orally available, ATP-competitive, small-molecule inhibitor of aurora kinases A, B, and C and… 
2009
2009
Aurora kinase inhibitor: AS703569
Aurora kinase (AK) functions are associated with centrosome maturation, mitotic spindle organization, chromosome separation and… 
2009
2009
The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in…
Abstract 730 Multi-targeted kinase inhibitors, when associated with manageable toxicity, offer the therapeutically desirable… 
2008
2008
Phase I, Dose-Escalation Study of 2 Dosing Regimens of AS703569, An Inhibitor of Aurora and Other Kinases, Administered Orally in Patients with Advanced Hematological Malignancies
Background: AS703569 is a novel, orally bioavailable, potent ATP-competitive, small molecule that inhibits all three aurora… 
2007
2007
The Novel Aurora Kinase Inhibitor AS703569 Shows Potent Anti-Tumor Activity in Acute Myeloid Leukemia (AML).
Aurora kinases have been implicated in the onset of several human cancers. They are overexpressed in different tumor types… 
2007
2007
A phase I two arm trial of AS703569 (R763), an orally available aurora kinase inhibitor, in subjects with solid tumors: preliminary results
2007
2007
Cellular and molecular mechanisms of action of AS703569, a novel aurora kinase inhibitor, in human cancer cell lines
C197 Background Inhibition of aurora kinases in tumor cells results in endoreduplication and cell death. AS703569 (formerly known… 
2007
2007
AS703569, a novel aurora kinase inhibitor, enhances the antiproliferative effects of other targeted therapies in human cancer cell lines
C188 Background AS703569 (formerly known as R763) is a novel highly potent orally available ATP competitive multi-kinase… 
2007
2007
Antiproliferative activity of AS703569, a novel aurora kinase inhibitor, given as a single agent and in combination with EGFR inhibitors in human head and neck squamous cell carcinoma (HNSCC).
C194 Background Aurora kinase functions are associated with centrosome maturation, spindle organization, chromosome separation… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)